Read the article: https://www.businesswire.com/news/home/20250904810311/en/Ginkgo-Datapoints-and-Apheris-Launch-Antibody-Developability-Consortium
Ginkgo Bioworks today announced a series of new initiatives from its Datapoints offering to accelerate the application of artificial intelligence in biologics drug discovery. These include a strategic partnership with Apheris to launch the Antibody Developability Consortium and, separately, the AbDev AI Competition.

Read the article: https://www.businesswire.com/news/home/20250904810311/en/Ginkgo-Datapoints-and-Apheris-Launch-Antibody-Developability-Consortium
The AISB Network launches AISB Bind, a new federated initiative through which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson, will collaboratively train an AI model to predict how small molecules bind to their protein targets
Five pharma companies fine-tuned OpenFold3 Preview 2 across 20,167 private structures, none of which left their environments. On 1,056 held-out structures, high-quality interface predictions rose from 35.6% to 52.1% and correct ligand poses from 28.9% to 46.8%, ahead of every public model. A first for federated drug discovery.

GEN published a thoughtful coverage of last month's Bio-IT World plenary keynote where JT from Apheris presented a session on federated learning and fine-tuning for drug discovery.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.

Robin Röhm
Co-Founder & CEO
© 2026 Apheris AI GmbH. All rights reserved.